Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Other Non-Current Assets (2020 - 2025)

Gain Therapeutics has reported Other Non-Current Assets over the past 6 years, most recently at $33694.0 for Q3 2025.

  • Quarterly results put Other Non-Current Assets at $33694.0 for Q3 2025, up 2.08% from a year ago — trailing twelve months through Sep 2025 was $33694.0 (up 2.08% YoY), and the annual figure for FY2024 was $31695.0, down 6.84%.
  • Other Non-Current Assets for Q3 2025 was $33694.0 at Gain Therapeutics, down from $36278.0 in the prior quarter.
  • Over the last five years, Other Non-Current Assets for GANX hit a ceiling of $79924.0 in Q2 2021 and a floor of $12008.0 in Q1 2021.
  • Median Other Non-Current Assets over the past 5 years was $31145.0 (2023), compared with a mean of $30700.3.
  • Biggest five-year swings in Other Non-Current Assets: plummeted 62.67% in 2022 and later soared 97.11% in 2023.
  • Gain Therapeutics' Other Non-Current Assets stood at $22111.0 in 2021, then surged by 39.38% to $30818.0 in 2022, then rose by 10.39% to $34021.0 in 2023, then dropped by 6.84% to $31695.0 in 2024, then grew by 6.31% to $33694.0 in 2025.
  • The last three reported values for Other Non-Current Assets were $33694.0 (Q3 2025), $36278.0 (Q2 2025), and $32542.0 (Q1 2025) per Business Quant data.